Scottish consensus statement on the role of FeNO in adult asthma

Chris Ruiwen Kuo, Mark Spears, John Haughney, Andrew Smith, Joy Miller, Tracey Bradshaw, Lorna Murray, Peter Williamson, Brian Lipworth (Lead / Corresponding author)

Research output: Contribution to journalReview article

Abstract

Fractional exhaled nitric oxide (FeNO) is the only available point of care test to assess type-2 inflammation in asthma. In making a diagnosis of asthma, FeNO should be used together with blood eosinophils and spirometry, alongside a history. Raised FeNO in conjunction with blood eosinophilia are treatable traits of type 2 inflammation in asthma, which in turn may guide personalised management. A FeNO suppression test can be used to assess adherence and device use with ICS therapy. Furthermore FeNO may be used to provide feedback to patients in response to ICS, especially when spirometry is normal. FeNO may facilitate appropriate referral to secondary care for more definitive specialist investigations. In summary, FeNO is cost effective in the diagnosis and management of asthma and should be incorporated into primary and secondary care as part of routine clinical practice.

Original languageEnglish
Pages (from-to)54-57
Number of pages4
JournalRespiratory Medicine
Volume155
Early online date6 Jul 2019
DOIs
Publication statusPublished - Aug 2019

Fingerprint

Nitric Oxide
Asthma
Secondary Care
Spirometry
Point-of-Care Systems
Inflammation
Eosinophilia
Eosinophils
Primary Health Care
Referral and Consultation
History
Costs and Cost Analysis
Equipment and Supplies

Keywords

  • Asthma
  • FeNO
  • Type 2 Inflammation

Cite this

Kuo, Chris Ruiwen ; Spears, Mark ; Haughney, John ; Smith, Andrew ; Miller, Joy ; Bradshaw, Tracey ; Murray, Lorna ; Williamson, Peter ; Lipworth, Brian. / Scottish consensus statement on the role of FeNO in adult asthma. In: Respiratory Medicine. 2019 ; Vol. 155. pp. 54-57.
@article{0151b594fa724f65b0e0b537c151e234,
title = "Scottish consensus statement on the role of FeNO in adult asthma",
abstract = "Fractional exhaled nitric oxide (FeNO) is the only available point of care test to assess type-2 inflammation in asthma. In making a diagnosis of asthma, FeNO should be used together with blood eosinophils and spirometry, alongside a history. Raised FeNO in conjunction with blood eosinophilia are treatable traits of type 2 inflammation in asthma, which in turn may guide personalised management. A FeNO suppression test can be used to assess adherence and device use with ICS therapy. Furthermore FeNO may be used to provide feedback to patients in response to ICS, especially when spirometry is normal. FeNO may facilitate appropriate referral to secondary care for more definitive specialist investigations. In summary, FeNO is cost effective in the diagnosis and management of asthma and should be incorporated into primary and secondary care as part of routine clinical practice.",
keywords = "Asthma, FeNO, Type 2 Inflammation",
author = "Kuo, {Chris Ruiwen} and Mark Spears and John Haughney and Andrew Smith and Joy Miller and Tracey Bradshaw and Lorna Murray and Peter Williamson and Brian Lipworth",
year = "2019",
month = "8",
doi = "10.1016/j.rmed.2019.07.010",
language = "English",
volume = "155",
pages = "54--57",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "Elsevier",

}

Kuo, CR, Spears, M, Haughney, J, Smith, A, Miller, J, Bradshaw, T, Murray, L, Williamson, P & Lipworth, B 2019, 'Scottish consensus statement on the role of FeNO in adult asthma', Respiratory Medicine, vol. 155, pp. 54-57. https://doi.org/10.1016/j.rmed.2019.07.010

Scottish consensus statement on the role of FeNO in adult asthma. / Kuo, Chris Ruiwen; Spears, Mark; Haughney, John; Smith, Andrew; Miller, Joy; Bradshaw, Tracey; Murray, Lorna; Williamson, Peter; Lipworth, Brian (Lead / Corresponding author).

In: Respiratory Medicine, Vol. 155, 08.2019, p. 54-57.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Scottish consensus statement on the role of FeNO in adult asthma

AU - Kuo, Chris Ruiwen

AU - Spears, Mark

AU - Haughney, John

AU - Smith, Andrew

AU - Miller, Joy

AU - Bradshaw, Tracey

AU - Murray, Lorna

AU - Williamson, Peter

AU - Lipworth, Brian

PY - 2019/8

Y1 - 2019/8

N2 - Fractional exhaled nitric oxide (FeNO) is the only available point of care test to assess type-2 inflammation in asthma. In making a diagnosis of asthma, FeNO should be used together with blood eosinophils and spirometry, alongside a history. Raised FeNO in conjunction with blood eosinophilia are treatable traits of type 2 inflammation in asthma, which in turn may guide personalised management. A FeNO suppression test can be used to assess adherence and device use with ICS therapy. Furthermore FeNO may be used to provide feedback to patients in response to ICS, especially when spirometry is normal. FeNO may facilitate appropriate referral to secondary care for more definitive specialist investigations. In summary, FeNO is cost effective in the diagnosis and management of asthma and should be incorporated into primary and secondary care as part of routine clinical practice.

AB - Fractional exhaled nitric oxide (FeNO) is the only available point of care test to assess type-2 inflammation in asthma. In making a diagnosis of asthma, FeNO should be used together with blood eosinophils and spirometry, alongside a history. Raised FeNO in conjunction with blood eosinophilia are treatable traits of type 2 inflammation in asthma, which in turn may guide personalised management. A FeNO suppression test can be used to assess adherence and device use with ICS therapy. Furthermore FeNO may be used to provide feedback to patients in response to ICS, especially when spirometry is normal. FeNO may facilitate appropriate referral to secondary care for more definitive specialist investigations. In summary, FeNO is cost effective in the diagnosis and management of asthma and should be incorporated into primary and secondary care as part of routine clinical practice.

KW - Asthma

KW - FeNO

KW - Type 2 Inflammation

UR - http://www.scopus.com/inward/record.url?scp=85068553685&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2019.07.010

DO - 10.1016/j.rmed.2019.07.010

M3 - Review article

VL - 155

SP - 54

EP - 57

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

ER -